加格列淨

**加格列淨**
法律規範狀態
法律規範	Investigational;
識別資訊
CAS號	1800115-22-3
UNII	WK4RT85HCA;
化學資訊
化學式	C25H29ClO6
摩爾質量	460.95 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES O([C@@H]1C[C@@]2([C@@](C2)(C1)[H])[H])C3=CC=C(CC4=CC(=CC=C4Cl)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C=C3;

加格列淨（分子式：C₂₅H₂₉ClO₆，化學名：(1S)-1,5-脫水-1-C-[3-[4-[(1α,3α,5α)-雙環[3.1.0]己-3-基氧基]苄基-4-氯苯基]-D-葡萄糖醇）是一種由四環醫藥研發的實驗性SGLT2抑制劑，^[1]用於治療糖尿病。^[2]

它可以2-氯-5-溴苯甲酸和3-環戊烯-1-醇為原料，經多步反應製得。^[3]

參考文獻[編輯]

^ Song, Ling; Yao, Xueting; Liu, Yang; Zhong, Wen; Jiang, Ji; Liu, Hongzhong; Zhou, Huimin; Shi, Chongtie; Zong, Kaiqi; Wang, Chong; Ma, Chuanxiang; Liu, Dongyang; Hu, Pei. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. European Journal of Pharmaceutical Sciences. April 2020, 147: 105281. doi:10.1016/j.ejps.2020.105281.
^ 惠升生物加格列净片. 四環醫藥. [2023-12-14].
^ Wu, Frank. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus). 2015. EP2891654.